DSID,AU,TI,JR,PY,VL,IS,PG,AB,SA,REGID,STD.IND,STD.DESIGN,STD.GEO.LOCATION,STD.PHASE,ARM.NUM,ARM.BLIND,ARM.RANDFLG,ARM.TRT,ARM.TRTCLASS,ARM.DOSE,ARM.DOSEU,ARM.ROUTE,ARM.REGIMEN,ARM.FORMULATION,N.STUDY,N.ARM,N.ARM.STATANAL,N.ARM.EVENT.SUBJ,STATANAL.POP,STATANAL.METHOD,STATANAL.IMP.METHOD,ARM.TIME1,ARM.TIME1U,ENDPOINT,BSL.STAT,BSL.VAL,BSL.VALU,BSL.VAR,BSL.VARU,BSL.LCI,BSL.UCI,CHBSL.STAT,CHBSL.VAL,CHBSL.VALU,CHBSL.VAR,CHBSL.VARU,CHBSL.LCI,CHBSL.UCI,RSP.STAT,RSP.VAL,RSP.VALU,RSP.VAR,RSP.VARU,RSP.LCI,RSP.UCI,PCHBSL.STAT,PCHBSL.VAL,PCHBSL.VAR,PCHBSL.VARU,PCHBSL.LCI,PCHBSL.UCI,ARM.PCT.MALE,ARM.AGE,ARM.AGEU
678,Rosenstock J; Jelaska A; Zeller C; Kim G; Broedl UC; Woerle HJ,"Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial",DIABETES.OBES.METAB,2015,17,10.0,936~948,,EMPA-REG BASAL,NCT01011868,T2D;Obesity,Parallel,DK;FR;IE;KR;PT;UK;US,Phase 2b,0.0,Double-Blind,True,placebo,Placebo,0,MG/DAY,ORAL,QD,,494,170.0,125,,FAS,ANCOVA,LOCF,18.0,WK,HbA1c,Mean,8.1,percent,0.07,SE,,,Mean,0.03,percent,0.07,SE,-0.109,0.169,Mean,8.1,percent,0.1,SE,7.902,8.298,Mean,0.37,,,,,53.0,58.1,YR
678,Rosenstock J; Jelaska A; Zeller C; Kim G; Broedl UC; Woerle HJ,"Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial",DIABETES.OBES.METAB,2015,17,10.0,936~948,,EMPA-REG BASAL,NCT01011868,T2D;Obesity,Parallel,DK;FR;IE;KR;PT;UK;US,Phase 2b,0.0,Double-Blind,True,placebo,Placebo,0,MG/DAY,ORAL,QD,,494,170.0,112,,FAS,ANCOVA,LOCF,78.0,WK,HbA1c,Mean,8.1,percent,0.07,SE,,,Mean,-0.05,percent,0.1,SE,-0.248,0.148,Mean,8.1,percent,0.1,SE,7.902,8.298,Mean,-0.617,,,,,53.0,58.1,YR
678,Rosenstock J; Jelaska A; Zeller C; Kim G; Broedl UC; Woerle HJ,"Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial",DIABETES.OBES.METAB,2015,17,10.0,936~948,,EMPA-REG BASAL,NCT01011868,T2D;Obesity,Parallel,DK;FR;IE;KR;PT;UK;US,Phase 2b,1.0,Double-Blind,True,empagliflozin,SGLT2,10,MG/DAY,ORAL,QD,,494,169.0,132,,FAS,ANCOVA,LOCF,18.0,WK,HbA1c,Mean,8.26,percent,0.07,SE,,,Mean,-0.58,percent,0.07,SE,-0.718,-0.442,Mean,7.7,percent,0.1,SE,7.502,7.898,Mean,-6.988,,,,,55.0,58.6,YR
678,Rosenstock J; Jelaska A; Zeller C; Kim G; Broedl UC; Woerle HJ,"Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial",DIABETES.OBES.METAB,2015,17,10.0,936~948,,EMPA-REG BASAL,NCT01011868,T2D;Obesity,Parallel,DK;FR;IE;KR;PT;UK;US,Phase 2b,1.0,Double-Blind,True,empagliflozin,SGLT2,10,MG/DAY,ORAL,QD,,494,169.0,127,,FAS,ANCOVA,LOCF,78.0,WK,HbA1c,Mean,8.26,percent,0.07,SE,,,Mean,-0.51,percent,0.09,SE,-0.688,-0.332,Mean,7.8,percent,0.1,SE,7.602,7.998,Mean,-6.145,,,,,55.0,58.6,YR
678,Rosenstock J; Jelaska A; Zeller C; Kim G; Broedl UC; Woerle HJ,"Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial",DIABETES.OBES.METAB,2015,17,10.0,936~948,,EMPA-REG BASAL,NCT01011868,T2D;Obesity,Parallel,DK;FR;IE;KR;PT;UK;US,Phase 2b,2.0,Double-Blind,True,empagliflozin,SGLT2,25,MG/DAY,ORAL,QD,,494,155.0,117,,FAS,ANCOVA,LOCF,18.0,WK,HbA1c,Mean,8.34,percent,0.08,SE,,,Mean,-0.75,percent,0.08,SE,-0.908,-0.592,Mean,7.6,percent,0.1,SE,7.402,7.798,Mean,-9.036,,,,,60.0,59.9,YR
678,Rosenstock J; Jelaska A; Zeller C; Kim G; Broedl UC; Woerle HJ,"Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial",DIABETES.OBES.METAB,2015,17,10.0,936~948,,EMPA-REG BASAL,NCT01011868,T2D;Obesity,Parallel,DK;FR;IE;KR;PT;UK;US,Phase 2b,2.0,Double-Blind,True,empagliflozin,SGLT2,25,MG/DAY,ORAL,QD,,494,155.0,110,,FAS,ANCOVA,LOCF,78.0,WK,HbA1c,Mean,8.34,percent,0.08,SE,,,Mean,-0.68,percent,0.09,SE,-0.858,-0.502,Mean,7.6,percent,0.1,SE,7.402,7.798,Mean,-8.193,,,,,60.0,59.9,YR
